Clinical Trial

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Study acronym: AMPLIFY
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-15
notable Trial sites reduced: 28 -> 22 locations 2026-05-15
Trial Details
NCT Number NCT06970847
Lead Sponsor Clarity Pharmaceuticals Ltd
Conditions Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant, Prostate Cancer Patients Treated by Radiotherapy, Cryotherapy
Enrollment 220 participants
Start Date 2025-05-16
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-14